|
1 Munoz N, Castellsague X, de Gonzalez AB, et al. Chapter 1: HPV in the etiology of human cancer [J]. Vaccine, 2006, 24(Suppl 3): S3/1-10.
|
|
2 Brink AA, Snijders PJ, Meijer CJ, et al. HPV testing in cervical screening [J]. Best Pract Res Clin Obstet Gynaecol, 2006, 20(2):253-266.
|
|
3 Lie AK, Kristensen G. Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical cancinoma[J]. Expert Rev Mol Diagn, 2008, 8(4): 405-415.
|
|
4 Castle PE, Dockter J, Giachetti C, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer [J]. Clin Cancer Res, 2007, 13(9): 2599-2605.
|
|
5 Andersson S, Hansson B, Norman I, et al. Expression of E6/E7 mRNA from ' high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a [J]. Int J Oncol, 2006, 29(3):705-711.
|
|
6 Molden T, Nygard JF, Kraus I, et al. Predicting CIN2 + when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear [J]. Int J Cancer, 2005, 114(6): 973-976.
|
|
7 Sæterdal IM, Juvet LK, Norderhaug IN. HPV RNA test for cervical cancer [R]. Rapport fra Kunnskapssenteret, NOKC nr 02-2008.
|
|
8 Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia [J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(10):2536-2545.
|
|
9 Bianchi A, Moret F, Desrues JM, et al. PreservCyt transport me dium used for the ThinPrep Pap test is a suitable medium for detection of Chlamydia trachomatis by the COBAS Amplicor CT/NG test: Results of a preliminary study and future implications [J]. J Clin Microbiol, 2002, 40(5): 1749-1754.
|
|
10 Cattani P, Zannoni GF, Ricci C, et al. Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix [J]. J Clin Microbiol, 2009, 47(12): 3895-3901.
|
|
11 Cattani P, Siddu A, D'Onghia S, et al. RNA (E6 and E7) assays versus DNA (E6 and E7) assays for risk evaluation for women infected with human papillomavirus [J]. J Clin Microbiol, 2009, 47 (7): 2136-2141.
|
|
12 Mockel J, Clad A, Endres AS, et al. HPV E6/E7 mRNA transcripts as predictors of high-grade epithelial cervix dysplasia [J]. Diagn Pathol, 2007, 2(Suppl 1) : S1.
|
|
13 Keegan H, Mc Inerney J, Pilkington L, et al. Comparison of HPV detection technologies: Hybrid capture 2, PreTectTM HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens [J]. J Virol Methods, 2009, 155(1): 61-66.
|
|
14 Oikonomou P, Messinis I, Tsezou A. DNA methylation is not likely to be responsible for hTERT expression in premalignant cervical lesions [J]. Exp Biol Med (Maywood), 2007, 232(7): 881-886.
|
|
15 Rosini S, Zappacosta R, Di Bonaventura G, et al. Management and triage of women with human papillomavirus infection in follow-up for low-grade cervical disease: Association of HPV-DNA AND RNA-based methods [J]. Int J Immunopathol Pharmacol, 2007, 20(2): 341-347.
|